Thomas Nirschl Email & Phone Number
Who is Thomas Nirschl? Overview
A concise factual answer block for searchers comparing this professional profile.
Thomas Nirschl is listed as Scientist Oncology Drug Discovery Unit at Takeda Oncology, a with 1651 employees, based in Canton, Massachusetts, United States. AeroLeads shows a matched LinkedIn profile for Thomas Nirschl.
Thomas Nirschl previously worked as Research Scientist I at Takeda Oncology and Postdoctoral Researcher at The Johns Hopkins University School Of Medicine. Thomas Nirschl holds Doctor Of Philosophy - Phd, Pathobiology from The Johns Hopkins University School Of Medicine.
Email format at Takeda Oncology
This section adds company-level context without repeating Thomas Nirschl's masked contact details.
Review company-level records connected to Thomas Nirschl before choosing the right outreach path.
About Thomas Nirschl
I am a highly motivated immune oncology scientist with extensive experience in lymphoid and myeloid translational research. I have performed research which leveraged human specimens and murine in vivo models to better understand therapeutic avenues to elicit anti-cancer immune responses in a translationally relevant fashion. I have significant experience with fundamental immune-oncology research techniques such as flow cytometry, as well as an interest in how new technologies can be used to rapidly advance project aims. I hope to use these experiences to help develop promising therapeutic candidates from the bench to the clinic and help improve the lives and outcomes of cancer patients.
Listed skills include Leadership, Cancer Research, Facs Analysis, Blotting, and 33 others.
Thomas Nirschl's current company
Company context helps verify the profile and gives searchers a useful next step.
Thomas Nirschl work experience
A career timeline built from the work history available for this profile.
Research Scientist I
Current
Postdoctoral Researcher
Coordinated with industry partners for project updates and direction. Generated and optimized in vitro screening assays for activity of a previously unpublished immune-oncology myeloid protein. Leveraged scRNAseq, WB, qRT-PCR and LC/MS/MS to elucidate correct readout targets and conditions. Characterized functional effect of novel protein deletion on FACS isolated intratumoral monocytes and macrophages.
Doctoral Candidate
Led three independent myeloid cell immune-oncology research projects. 1) Investigating the transcriptional profiles of intratumoral monocytes and macrophages rapidly isolated from primary untreated human clear cell renal cell carcinoma (ccRCC) specimens, 2) elucidating the role of PI3Kgamma in immunosuppressive tumor associated macrophages in prostate cancer, 3) investigation of the mechanistic role of a previously unpublished molecule expressed on myeloid cells and its immunotherapeutic potential across multiple preclinical models of cancer.Utilized small molecule inhibitors against PI3Kgamma in vitro to screen for phenotypic differences. Performed flow cytometry, western blotting, and qRT-PCR to interrogate phenotypic alterations. Utilized multiple in vivo genetic knockout models and pharmacological inhibition models (oral gavage, intraperitoneal injections, subcutaneous injection) to test the effects of disrupting various protein signaling pathways on tumor growth. Performed extensive single cell RNA sequencing experiments to investigate the transcriptional alterations after genetic deletion of the novel molecule. Capitalized on the existing RNAseq analysis platform Ingenuity Pathway Analysis (IPA) to produce hypothesis generating data. These data identify testable putative transcription factors and pathways controlled by this novel molecule and are being leveraged to generate in vitro screening assays for therapeutic molecules. Utilized LC/MS/MS to successfully test specific hypotheses generated from the scRNAseq data analysis. Coordinated with industry partners to generate and test specific antibody clones targeting the novel molecule. Using molecular cloning techniques, generated an in vitro proximity ligation assay (PLA) cell line model to screen for cytoplasmic interacting partners after novel protein ligation. Trained and managed 5 rotation students, conceptualizing, and leading the experimental designs of multiple scientific projects.
Teaching Assistant
Coordinated and led a weekly small group session, focused on discussing primary research articles which underlay a wide array of immunology concepts and techniques described in the lecture portion of the class. Led review sessions, held office hours, created exam questions and graded exams.
Teaching Assistant
Coordinated and led a weekly small group session, focused on discussing primary research articles which underlay a wide array of immunology concepts and techniques described in the lecture portion of the class. Led review sessions, held office hours, created exam questions and graded exams.
Research Technologist
Developed and optimized a standard operating procedure (SOP) for rapid FACS isolation of lymphocytes from fresh primary human peripheral blood and tumor specimens. This SOP allowed isolation of pure intratumoral lymphocytes within 4-5 hours of clinical resection of tumor tissue, through strong coordination and communication across multiple healthcare and research teams. Generated and optimized a 9-color flow cytometry panel to isolate primary lymphocytes from clinical patient specimens. This panel focused on identifying naïve and effector CD8+ T cells, and naïve, effector and regulatory CD4+ T cells. Optimized direct FACS sorting into lysis buffer for RNA extraction for very low (>20,000) cell counts. Was able to successfully and reproducibly isolate RNAseq quality RNA from samples as low as ~500 cells. Developed and optimized three 8-10 color flow panels for phenotyping lymphocytes from peripheral and tumor sites from samples obtained from clinical trial specimens. These panels focused on 1) Surface markers, 2) Transcription Factors, 3) Cytokine production.Isolated FFPE RNA from archived human tissue sources for Nanostring analysis. Performed in vitro cell culture experiments testing the effect of inflammatory cytokines on prostate cancer cell phenotypes. Used the Small Animal Radiation Research Platform (SARRP) to study the effect of focal brain irradiation on circulating immune cells. Determined the absolute cell counts of peripheral immune cells using flow cytometry cell counting bead kit. Performed ELISA’s to determine cytokine alterations in lymph nodes after radiation. Maintained an animal colony of >30 strains. Weaned, genotyped (PCR, flow cytometry) and bred each strain successfully for 4 years before transitioning into a Ph.D. training program. Organized and maintained laboratory reagent and consumables stocks, animal protocols, new student on-boarding procedures, and monitored funding utilization.
Colleagues at Takeda Oncology
Other employees you can reach at takedaoncology.com. View company contacts for 1651 employees →
P Swirka
Colleague at Takeda OncologyCambridge, Massachusetts, United States
View →
MA
Maria Alantzas
Colleague at Takeda OncologyCambridge, Massachusetts, United States
View →
SY
Sydney Yuen
Colleague at Takeda OncologyCambridge, Massachusetts, United States
View →
MZ
Matthias Zunhammer
Colleague at Takeda OncologyBerlin, Germany
View →
SB
Soraya Benchenni,
Colleague at Takeda OncologyGreater Paris Metropolitan Region, France
View →
YM
Yingchun May Ye
Colleague at Takeda OncologyCambridge, Massachusetts, United States
View →
LF
Liam Fraser
Colleague at Takeda OncologyBirmingham, Michigan, United States
View →
EK
E.R.Naveen Kumar
Colleague at Takeda OncologyAndhra Pradesh, India
View →
JB
Jayson Boon
Colleague at Takeda OncologyMinneapolis, Minnesota, United States
View →
NM
Nancy Mcdevitt
Colleague at Takeda OncologyWakefield, Massachusetts, United States
View →
Thomas Nirschl education
Doctor Of Philosophy - Phd, Pathobiology
Bachelor'S Of Science, Biology
Frequently asked questions about Thomas Nirschl
Quick answers generated from the profile data available on this page.
What company does Thomas Nirschl work for?
Thomas Nirschl works for Takeda Oncology.
What is Thomas Nirschl's role at Takeda Oncology?
Thomas Nirschl is listed as Scientist Oncology Drug Discovery Unit at Takeda Oncology.
Where is Thomas Nirschl based?
Thomas Nirschl is based in Canton, Massachusetts, United States while working with Takeda Oncology.
What companies has Thomas Nirschl worked for?
Thomas Nirschl has worked for Takeda Oncology, The Johns Hopkins University School Of Medicine, and Johns Hopkins School Of Medicine.
Who are Thomas Nirschl's colleagues at Takeda Oncology?
Thomas Nirschl's colleagues at Takeda Oncology include P Swirka, Maria Alantzas, Sydney Yuen, Matthias Zunhammer, and Soraya Benchenni,.
How can I contact Thomas Nirschl?
You can use AeroLeads to view verified contact signals for Thomas Nirschl at Takeda Oncology, including work email, phone, and LinkedIn data when available.
What schools did Thomas Nirschl attend?
Thomas Nirschl holds Doctor Of Philosophy - Phd, Pathobiology from The Johns Hopkins University School Of Medicine.
What skills is Thomas Nirschl known for?
Thomas Nirschl is listed with skills including Leadership, Cancer Research, Facs Analysis, Blotting, Multi Color Flow Cytometry, Cytometry, Flowjo, and Cell Biology.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trialCheck these profiles if this is not the Thomas Nirschl you were looking for.
View similar profiles